突变型-话题@MedSci - williamhill asia

#突变型#

89篇内容 | 1646人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2041441, encodeId=a7bd20414411e, content=<a href='/topic/show?id=baade55002a' target=_blank style='color:#2F92EE;'>#突变型#</a>, objectTitle=Lancet oncol：信迪利单抗+IBI305+化疗治疗EGFR TKI治疗后进展的EGFR突变型NSCLC, objectType=article, longId=734225, objectId=0acbe3422547, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0acbe3422547, replyNumber=0, likeNumber=82, createdTime=2023-04-03, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0acbe3422547, moduleTitle=Lancet oncol：信迪利单抗+IBI305+化疗治疗EGFR TKI治疗后进展的EGFR突变型NSCLC, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=0acbe3422547)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2041439, encodeId=b989204143993, content=<a href='/topic/show?id=baade55002a' target=_blank style='color:#2F92EE;'>#突变型#</a>, objectTitle=J Clin Oncol：维奈托克联合吉特替尼治疗FLT3突变型急性髓系白血病, objectType=article, longId=734106, objectId=f1c8e341064d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f1c8e341064d, replyNumber=0, likeNumber=89, createdTime=2022-10-23, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f1c8e341064d, moduleTitle=J Clin Oncol：维奈托克联合吉特替尼治疗FLT3突变型急性髓系白血病, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=f1c8e341064d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2041438, encodeId=a15a20414381f, content=<a href='/topic/show?id=baade55002a' target=_blank style='color:#2F92EE;'>#突变型#</a>, objectTitle=J Immunother Cancer：抗PD1±抗CTLA4治疗BRAF/MEK抑制剂治疗失败的V600BRAF突变型转移性黑色素瘤, objectType=article, longId=731840, objectId=fa30e31840a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fa30e31840a0, replyNumber=0, likeNumber=66, createdTime=2022-07-24, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fa30e31840a0, moduleTitle=J Immunother Cancer：抗PD1±抗CTLA4治疗BRAF/MEK抑制剂治疗失败的V600BRAF突变型转移性黑色素瘤, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=fa30e31840a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2041440, encodeId=e353204144054, content=<a href='/topic/show?id=baade55002a' target=_blank style='color:#2F92EE;'>#突变型#</a>, objectTitle=J Clin Oncol：Encorafenib联合Binimetinib治疗BRAF V600突变型黑色素瘤的长期效益, objectType=article, longId=734132, objectId=690de34132b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=690de34132b5, replyNumber=0, likeNumber=66, createdTime=2022-09-04, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=690de34132b5, moduleTitle=J Clin Oncol：Encorafenib联合Binimetinib治疗BRAF V600突变型黑色素瘤的长期效益, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=690de34132b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2041434, encodeId=bcfc20414344b, content=<a href='/topic/show?id=baade55002a' target=_blank style='color:#2F92EE;'>#突变型#</a>, objectTitle=NEJM：采用Trastuzumab Deruxtecan治疗转移性HER2突变型非小细胞肺癌, objectType=article, longId=295543, objectId=761e29554381, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=761e29554381, replyNumber=0, likeNumber=75, createdTime=2022-07-09, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=761e29554381, moduleTitle=NEJM：采用Trastuzumab Deruxtecan治疗转移性HER2突变型非小细胞肺癌, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=761e29554381)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2041430, encodeId=8e822041430b3, content=<a href='/topic/show?id=baade55002a' target=_blank style='color:#2F92EE;'>#突变型#</a>, objectTitle=Lancet Oncol：IDH2抑制剂Enasidenib联合阿扎胞苷治疗IDH2突变型急性髓系白血病的疗效和安全性, objectType=article, longId=218905, objectId=80032189050a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=80032189050a, replyNumber=0, likeNumber=73, createdTime=2022-06-08, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=80032189050a, moduleTitle=Lancet Oncol：IDH2抑制剂Enasidenib联合阿扎胞苷治疗IDH2突变型急性髓系白血病的疗效和安全性, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=80032189050a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2041432, encodeId=c11f204143236, content=<a href='/topic/show?id=baade55002a' target=_blank style='color:#2F92EE;'>#突变型#</a>, objectTitle=Clinical Lung Cancer：HER2基因改变在EGFR突变型非小细胞肺癌（NSCLC）中的作用, objectType=article, longId=220913, objectId=6a77220913bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6a77220913bb, replyNumber=0, likeNumber=125, createdTime=2022-06-24, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6a77220913bb, moduleTitle=Clinical Lung Cancer：HER2基因改变在EGFR突变型非小细胞肺癌（NSCLC）中的作用, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=6a77220913bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2041442, encodeId=a0a8204144215, content=<a href='/topic/show?id=baade55002a' target=_blank style='color:#2F92EE;'>#突变型#</a>, objectTitle=J Clin Oncol：HCT后采用Eprenetapopt+阿扎胞苷维持治疗TP53突变型AML和MDS的效益, objectType=article, longId=734319, objectId=1531e34319fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1531e34319fe, replyNumber=0, likeNumber=109, createdTime=2022-11-29, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1531e34319fe, moduleTitle=J Clin Oncol：HCT后采用Eprenetapopt+阿扎胞苷维持治疗TP53突变型AML和MDS的效益, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=1531e34319fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2041435, encodeId=99a62041435d0, content=<a href='/topic/show?id=baade55002a' target=_blank style='color:#2F92EE;'>#突变型#</a>, objectTitle=Eur J Cancer：MEK抑制剂治疗NRAS突变型转移性黑色素瘤的真实临床疗效, objectType=article, longId=300803, objectId=cb143008036b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb143008036b, replyNumber=0, likeNumber=84, createdTime=2022-04-10, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb143008036b, moduleTitle=Eur J Cancer：MEK抑制剂治疗NRAS突变型转移性黑色素瘤的真实临床疗效, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=cb143008036b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2041431, encodeId=db54204143115, content=<a href='/topic/show?id=baade55002a' target=_blank style='color:#2F92EE;'>#突变型#</a>, objectTitle=Clinical Lung Cancer：HER2基因改变在EGFR突变型非小细胞肺癌（NSCLC）中的作用, objectType=article, longId=219107, objectId=6aae21910e96, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6aae21910e96, replyNumber=0, likeNumber=62, createdTime=2022-06-30, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6aae21910e96, moduleTitle=Clinical Lung Cancer：HER2基因改变在EGFR突变型非小细胞肺癌（NSCLC）中的作用, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=6aae21910e96)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2041437, encodeId=4fea204143edd, content=<a href='/topic/show?id=baade55002a' target=_blank style='color:#2F92EE;'>#突变型#</a>, objectTitle=“双靶组合”新适应症在我国获批，「达拉非尼」联合「曲美替尼」为BRAF V600突变型非小细胞肺癌患者带来新选择, objectType=article, longId=301601, objectId=430a301601f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=430a301601f4, replyNumber=0, likeNumber=77, createdTime=2022-12-06, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=430a301601f4, moduleTitle=“双靶组合”新适应症在我国获批，「达拉非尼」联合「曲美替尼」为BRAF V600突变型非小细胞肺癌患者带来新选择, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=430a301601f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2041436, encodeId=f234204143605, content=<a href='/topic/show?id=baade55002a' target=_blank style='color:#2F92EE;'>#突变型#</a>, objectTitle=Eur J Cancer：EGFR突变型肺癌的组织学转化概率及临床病程, objectType=article, longId=301130, objectId=be42301130c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=be42301130c7, replyNumber=0, likeNumber=75, createdTime=2022-11-02, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=be42301130c7, moduleTitle=Eur J Cancer：EGFR突变型肺癌的组织学转化概率及临床病程, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=be42301130c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2041429, encodeId=23a82041429fe, content=<a href='/topic/show?id=baade55002a' target=_blank style='color:#2F92EE;'>#突变型#</a>, objectTitle=Cancer Commun：中国KRAS突变型非小细胞肺癌患者化疗后的临床特点及预后分析, objectType=article, longId=218842, objectId=20e9218842d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=20e9218842d0, replyNumber=0, likeNumber=79, createdTime=2021-12-28, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=20e9218842d0, moduleTitle=Cancer Commun：中国KRAS突变型非小细胞肺癌患者化疗后的临床特点及预后分析, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=20e9218842d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2041433, encodeId=283b204143369, content=<a href='/topic/show?id=baade55002a' target=_blank style='color:#2F92EE;'>#突变型#</a>, objectTitle=Clin Cancer Res：突变型IDH1/2双重抑制剂Vorasidenib治疗复发/进展胶质瘤的效果, objectType=article, longId=292034, objectId=9c622920349a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c622920349a, replyNumber=0, likeNumber=59, createdTime=2022-01-20, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c622920349a, moduleTitle=Clin Cancer Res：突变型IDH1/2双重抑制剂Vorasidenib治疗复发/进展胶质瘤的效果, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=9c622920349a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2041427, encodeId=0549204142e50, content=<a href='/topic/show?id=baade55002a' target=_blank style='color:#2F92EE;'>#突变型#</a>, objectTitle=Clin Cancer Res：Palbociclib+Vemurafenib治疗BRAF突变型转移性黑色素瘤, objectType=article, longId=214664, objectId=c24a214664ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c24a214664ad, replyNumber=0, likeNumber=83, createdTime=2021-12-27, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c24a214664ad, moduleTitle=Clin Cancer Res：Palbociclib+Vemurafenib治疗BRAF突变型转移性黑色素瘤, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=c24a214664ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2041424, encodeId=5f082041424be, content=<a href='/topic/show?id=baade55002a' target=_blank style='color:#2F92EE;'>#突变型#</a>, objectTitle=J Clin Oncol：Eprenetapopt联合阿扎胞苷治疗TP53突变型MDS和AML, objectType=article, longId=207335, objectId=402b20e335fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=402b20e335fd, replyNumber=0, likeNumber=77, createdTime=2021-07-07, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=402b20e335fd, moduleTitle=J Clin Oncol：Eprenetapopt联合阿扎胞苷治疗TP53突变型MDS和AML, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=402b20e335fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2041415, encodeId=337820414156c, content=<a href='/topic/show?id=baade55002a' target=_blank style='color:#2F92EE;'>#突变型#</a>, objectTitle=J Thromb Haemost：ALK和EGFR突变型肺癌患者血栓栓塞风险分析, objectType=article, longId=204723, objectId=251b204e2375, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=251b204e2375, replyNumber=0, likeNumber=65, createdTime=2021-05-03, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=251b204e2375, moduleTitle=J Thromb Haemost：ALK和EGFR突变型肺癌患者血栓栓塞风险分析, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=251b204e2375)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2041426, encodeId=1a6520414266f, content=<a href='/topic/show?id=baade55002a' target=_blank style='color:#2F92EE;'>#突变型#</a>, objectTitle=Lancet respirat：同济大学3期临床试验揭示埃克替尼在EGFR突变型晚期NSCLC中的疗效, objectType=article, longId=214456, objectId=4803214456af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4803214456af, replyNumber=0, likeNumber=109, createdTime=2021-10-29, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4803214456af, moduleTitle=Lancet respirat：同济大学3期临床试验揭示埃克替尼在EGFR突变型晚期NSCLC中的疗效, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=4803214456af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2041428, encodeId=9f4920414282f, content=<a href='/topic/show?id=baade55002a' target=_blank style='color:#2F92EE;'>#突变型#</a>, objectTitle=Clin Cancer Res：突变型IDH1/2双重抑制剂Vorasidenib治疗复发/进展胶质瘤的效果, objectType=article, longId=215832, objectId=fb1921583209, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fb1921583209, replyNumber=0, likeNumber=62, createdTime=2022-06-30, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fb1921583209, moduleTitle=Clin Cancer Res：突变型IDH1/2双重抑制剂Vorasidenib治疗复发/进展胶质瘤的效果, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=fb1921583209)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2041410, encodeId=96cb204141006, content=<a href='/topic/show?id=baade55002a' target=_blank style='color:#2F92EE;'>#突变型#</a>, objectTitle=Nat Med: 联合PD-1、BRAF和MEK抑制剂治疗晚期BRAF突变型黑色素瘤, objectType=article, longId=201779, objectId=f6f5201e7983, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f6f5201e7983, replyNumber=0, likeNumber=66, createdTime=2020-12-26, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f6f5201e7983, moduleTitle=Nat Med: 联合PD-1、BRAF和MEK抑制剂治疗晚期BRAF突变型黑色素瘤, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=f6f5201e7983)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] williamhill asia 话题小助手

突变型

2020-05-29

heli0118 (审核中...)

前往app查看评论内容

#突变型#

Lancet oncol：信迪利单抗+IBI305+化疗治疗EGFR TKI治疗后进展的EGFR突变型NSCLC

2023-04-03

zhouqu_8 (审核中...)

前往app查看评论内容

#突变型#

J Clin Oncol：维奈托克联合吉特替尼治疗FLT3突变型急性髓系白血病

2022-10-23

zhouqu_8 (审核中...)

前往app查看评论内容

#突变型#

J Immunother Cancer：抗PD1±抗CTLA4治疗BRAF/MEK抑制剂治疗失败的V600BRAF突变型转移性黑色素瘤

2022-07-24

heli0118 (审核中...)

前往app查看评论内容

#突变型#

J Clin Oncol：Encorafenib联合Binimetinib治疗BRAF V600突变型黑色素瘤的长期效益

2022-09-04

zhouqu_8 (审核中...)

前往app查看评论内容

#突变型#

NEJM：采用Trastuzumab Deruxtecan治疗转移性HER2突变型非小细胞肺癌

2022-07-09

zhouqu_8 (审核中...)

前往app查看评论内容

#突变型#

Lancet Oncol：IDH2抑制剂Enasidenib联合阿扎胞苷治疗IDH2突变型急性髓系白血病的疗效和安全性

2022-06-08

zhouqu_8 (审核中...)

前往app查看评论内容

#突变型#

Clinical Lung Cancer：HER2基因改变在EGFR突变型非小细胞肺癌（NSCLC）中的作用

2022-06-24

heli0118 (审核中...)

前往app查看评论内容

#突变型#

J Clin Oncol：HCT后采用Eprenetapopt+阿扎胞苷维持治疗TP53突变型AML和MDS的效益

2022-11-29

zhouqu_8 (审核中...)

前往app查看评论内容

#突变型#

Eur J Cancer：MEK抑制剂治疗NRAS突变型转移性黑色素瘤的真实临床疗效

2022-04-10

zhouqu_8 (审核中...)

前往app查看评论内容

#突变型#

Clinical Lung Cancer：HER2基因改变在EGFR突变型非小细胞肺癌（NSCLC）中的作用

2022-06-30

zhouqu_8 (审核中...)

前往app查看评论内容

#突变型#

“双靶组合”新适应症在我国获批，「达拉非尼」联合「曲美替尼」为BRAF V600突变型非小细胞肺癌患者带来新选择

2022-12-06

zhouqu_8 (审核中...)

前往app查看评论内容

#突变型#

Eur J Cancer：EGFR突变型肺癌的组织学转化概率及临床病程

2022-11-02

heli0118 (审核中...)

前往app查看评论内容

#突变型#

Cancer Commun：中国KRAS突变型非小细胞肺癌患者化疗后的临床特点及预后分析

2021-12-28

zhouqu_8 (审核中...)

前往app查看评论内容

#突变型#

Clin Cancer Res：突变型IDH1/2双重抑制剂Vorasidenib治疗复发/进展胶质瘤的效果

2022-01-20

heli0118 (审核中...)

前往app查看评论内容

#突变型#

Clin Cancer Res：Palbociclib+Vemurafenib治疗BRAF突变型转移性黑色素瘤

2021-12-27

heli0118 (审核中...)

前往app查看评论内容

#突变型#

J Clin Oncol：Eprenetapopt联合阿扎胞苷治疗TP53突变型MDS和AML

2021-07-07

heli0118 (审核中...)

前往app查看评论内容

#突变型#

J Thromb Haemost：ALK和EGFR突变型肺癌患者血栓栓塞风险分析

2021-05-03

heli0118 (审核中...)

前往app查看评论内容

#突变型#

Lancet respirat：同济大学3期临床试验揭示埃克替尼在EGFR突变型晚期NSCLC中的疗效

2021-10-29

heli0118 (审核中...)

前往app查看评论内容

#突变型#

Clin Cancer Res：突变型IDH1/2双重抑制剂Vorasidenib治疗复发/进展胶质瘤的效果

2022-06-30

heli0118 (审核中...)

前往app查看评论内容

#突变型#

Nat Med: 联合PD-1、BRAF和MEK抑制剂治疗晚期BRAF突变型黑色素瘤

2020-12-26

科室
- - 订阅+
  - 更多科室
工具
服务